LeMaitre Vascular, Inc. (NASDAQ: LMAT) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $1.7B. The Maz Rating grades it against the other companies in its sector.
LeMaitre Vascular, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $76.10, LeMaitre Vascular, Inc. trades at 27.1x trailing earnings, 6.4x sales and 4.0x book value, with an EV/EBITDA of 20.7. Over the last twelve months it generated about $271M of revenue and $64M of net income. It runs a gross margin of 72.0%, an operating margin of 27.7% and a net margin of 23.5%. It shows return on equity of 15.3%, return on invested capital of 9.3% and a free cash flow yield of 3.9%. On the balance sheet: a debt-to-equity ratio of 0.44 and a current ratio of 14.60. Over the past 52 weeks the share price ranged from $75.67 to $118.01, with a beta of 0.49.
LeMaitre Vascular, Inc. pays a dividend yielding 1.25%, with 34% of earnings paid out. Its Maz Dividend Score is 3.70 out of 5, ranked against the other dividend payers in its sector (Safety 2.77, Growth 4.70, Yield 2.30, Consistency 3.34).
20 Wall Street analyst ratings cover the stock: 14 Buy and 6 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, LeMaitre Vascular, Inc. (LMAT) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 9.13% / 30% · (Cash+Inv) / Mkt Cap (36m) 21.0% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 9.13% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 21.0% / 33% · Receivables / Mkt Cap (36m) 1.93% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 9.13% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 21.0% / 33.33% · Receivables / Mkt Cap (24m) 1.93% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 26.6% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 58.7% / 33.33% · Receivables / Avg Assets (4Q) 5.54% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 25.8% / 33.33% · (Cash+ST Inv) / Total Assets 59.4% / 33.33% · (Cash+Recv) / Total Assets 64.9% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, LeMaitre Vascular, Inc. (LMAT) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. LeMaitre Vascular, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
LeMaitre Vascular, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.